|
|
Article: Other News To Note.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
o Amylin Pharmaceuticals Inc., of San Diego, and Eli Lilly and Co., of Indianapolis, said the European Committee for Medicinal Products for Human Use recommended approval of exenatide in Type II diabetes. Marketing authorization by the European Commission is expected later this year. If approved, the drug will be marketed in Europe as Byetta, the same brand name as in the U.S.
o Auxilium Pharmaceuticals Inc., of Malvern, Pa., closed its previously reported $43.3 million equity sale of 5.5 million common shares at $8.50 apiece. The specialty pharmaceutical company expects to use net proceeds for general corporate purposes, including working capital, product ...
Related newspaper, magazine, and journal articles:
|
|
Article: HEAD, NECK TUMORS' GROWTH HALTED ONYX'S VIRAL ANTICANCER DRUG ...
BIOWORLD Today;
November 24, 1998 ;
700+ words
... ... The company said efficacy has been seen in mouse tumor models. Results of the Phase II study were presented Saturday in San Diego at the Seventh International Conference on Gene Therapy of Cancer. Onyx's stock (NASDAQ:ONXX), which was as low as ...
|
|